For people living with severe depression, the hardest part is not always sadness. Many describe something even more troubling: the feeling that life has lost its color.
Activities they once loved no longer seem rewarding. Spending time with family and friends brings little enjoyment.
Motivation disappears, and everyday tasks feel like a burden. This symptom, known as anhedonia, is one of the most stubborn and disabling features of depression.
A new study from Sweden suggests that a medication commonly used for Parkinson’s disease may help address this problem.
Researchers from Lund University and Region Skåne found that the drug pramipexole improved motivation and pleasure in people with treatment-resistant depression. Their findings were published in Nature Medicine.
Depression is one of the most common mental health disorders in the world. It affects people of all ages and backgrounds. Symptoms often include low mood, fatigue, feelings of hopelessness, difficulty concentrating, changes in sleep, and loss of interest in daily activities.
While many people respond to antidepressants, a large number continue to experience symptoms despite trying multiple treatments.
Treatment-resistant depression presents a major challenge for doctors. When standard therapies fail, patients often face years of ongoing symptoms that interfere with work, relationships, and overall well-being.
Researchers are therefore searching for new approaches that target aspects of depression not adequately addressed by existing medications.
One area receiving growing attention is the brain’s reward system. This system helps people experience pleasure, satisfaction, and motivation. Scientists believe disruptions in this network may contribute to anhedonia. A key chemical involved in the reward system is dopamine.
Dopamine acts as a messenger between brain cells. It plays an important role in helping people pursue goals, anticipate rewards, and experience enjoyment. Problems with dopamine signaling have been linked to several neurological and psychiatric disorders.
Pramipexole was originally developed to treat Parkinson’s disease, a condition in which dopamine-producing brain cells gradually deteriorate.
By stimulating dopamine receptors, the drug helps improve movement symptoms in Parkinson’s patients. Researchers wondered whether the same mechanism might help restore motivation in people with depression.
To test this possibility, the Swedish team recruited patients who had depression marked by significant anhedonia. Participants continued taking their regular antidepressant medications and received either pramipexole or a placebo in addition to their existing treatment.
The study lasted nine weeks. During that period, researchers measured changes in symptoms and monitored participants carefully. The results showed that people receiving pramipexole experienced greater improvements in motivation and ability to enjoy activities compared with those receiving placebo.
Many participants who benefited from the treatment chose to continue using the medication after the main study ended. Researchers followed these individuals for six additional months and found that the positive effects generally continued over time.
The research team also wanted to understand what was happening inside the brain. Using highly advanced imaging technology, they examined brain activity in regions involved in reward processing. The scans suggested that pramipexole improved the function of neural circuits associated with motivation and pleasure.
Researchers collected another type of evidence as well. Participants wore activity monitors that tracked movement during everyday life. Those taking pramipexole showed higher levels of physical activity, suggesting they were becoming more engaged with daily tasks and routines.
The treatment appeared to be reasonably well tolerated. Most participants completed the study, and serious problems were uncommon. The most frequently reported side effects included nausea, dizziness, and sleep-related difficulties. Doctors were often able to reduce these issues by adjusting the dose.
Despite the encouraging results, researchers caution that monitoring remains essential. Some dopamine-related drugs can occasionally lead to impulse-control problems, such as compulsive shopping or gambling. Daytime fatigue can also occur in some individuals.
The study highlights the growing importance of drug repurposing in medicine. Developing a completely new medication can take many years and cost enormous amounts of money. By identifying new uses for existing drugs, researchers may be able to bring effective treatments to patients more quickly.
What makes these findings particularly noteworthy is their focus on anhedonia. Many current antidepressants help reduce sadness and anxiety but do not fully restore motivation and pleasure. By directly targeting the brain’s dopamine system, pramipexole may address a symptom that has remained difficult to treat.
Looking at the evidence overall, the study provides encouraging support for a new treatment strategy for depression. The combination of symptom improvement, brain imaging results, and increased daily activity strengthens confidence in the findings.
However, larger clinical trials will still be needed to confirm effectiveness and safety in broader populations. The results suggest that dopamine-targeting therapies may play an important role in the future of depression treatment, particularly for people who have not benefited from conventional antidepressants.
If you care about health, please read studies that scientists find a core feature of depression and this metal in the brain strongly linked to depression.
For more health information, please see recent studies about drug for mental health that may harm the brain, and results showing this therapy more effective than ketamine in treating severe depression.
